Great points. I would guess that there are still uncertainties as relates to potential unknown adverse events in a transgenically derived product that may not become apparent until the product is released and the number of people treated is high enough to uncover a potentially serious problem that occurs with a low frequency. Look at the late thrombosis issue with drug eluting stents. They started out like the greatest thing since short pants and then the enthusiam cooled down when it became apparent that patients would need to be on potent anti-platelet agents for years or risk sudden death. I wouldn't be surprised if the market stays cautious until Atryn has been around for a while. Theoretically the products should be much easier to produce at a lower cost with a better safety profile than the plasma derived alternative and work as well or better but that has yet to be proven. The proof is in the goat's milk pudding.
Market Data 
Markets 
AI
